nach oben

American Journal of Clinical Dermatology

Erschienen in:

01.12.2015 | Review Article

Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: An Update

verfasst von: Roni P. Dodiuk-Gad, Wen-Hung Chung, Laurence Valeyrie-Allanore, Neil H. Shear

Erschienen in: American Journal of Clinical Dermatology | Ausgabe 6/2015

Einloggen, um Zugang zu erhalten

Abstract

Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are life-threatening mucocutaneous reactions, predominantly drug induced. The mortality rates for SJS and TEN are as high as 30 %, and short- and long-term morbidities are very common. SJS/TEN is one of the few dermatological diseases that constitute a true medical emergency. Early recognition and prompt and appropriate management can be lifesaving. In recent years, our understanding of the pathogenesis, clinical presentation, and management of SJS/TEN has improved. Nevertheless, in 2015, there are still no internationally accepted management guidelines. This review summarizes up-to-date insights on SJS/TEN and describes a protocol for assessment and treatment. We hope these suggested guidelines serve as a practical clinical tool in the management of SJS/TEN. The classic manifestation of SJS/TEN consists of initial “flu-like” symptoms (malaise, fever, anorexia) in the prodromal phase, followed by cutaneous and mucous membrane (ocular, oral, and genital) inflammation and pain, and other systemic involvement. Symptoms usually begin 4–28 days after the onset of drug intake. Treatment is multidisciplinary and includes identification and withdrawal of the culprit drug, transfer to a specialist unit, supportive care, medical treatment, communication, and provision of appropriate information and emotional support.

Stevens A, Johnson F. A new eruptive fever associated with stomatitis and ophthalmia: report of two cases in children. Arch Pediatr Adolesc Med. 1922;24(6):526.

Lyell A. Toxic epidermal necrolysis: an eruption resembling scalding of the skin. Br J Dermatol. 1956;68(11):355–61.PubMedCrossRef

Knowles S, Shear NH. Clinical risk management of Stevens–Johnson syndrome/toxic epidermal necrolysis spectrum. Dermatol Ther. 2009;22(5):441–51.PubMedCrossRef

Roujeau JC, Huynh TN, Bracq C, et al. Genetic susceptibility to toxic epidermal necrolysis. Arch Dermatol. 1987;123(9):1171–3.PubMedCrossRef

Chung WH, Hung SI, Hong HS, et al. Medical genetics: a marker for Stevens–Johnson syndrome. Nature. 2004;428(6982):486.PubMedCrossRef

Kaniwa N, Saito Y, Aihara M, et al. HLA-B*1511 is a risk factor for carbamazepine-induced Stevens–Johnson syndrome and toxic epidermal necrolysis in Japanese patients. Epilepsia. 2010;51(12):2461–5.PubMedCrossRef

Kim SH, Lee KW, Song WJ, et al. Carbamazepine-induced severe cutaneous adverse reactions and HLA genotypes in Koreans. Epilepsy Res. 2011;97(1–2):190–7.PubMedCrossRef

Shi YW, Min FL, Qin B, et al. Association between HLA and Stevens–Johnson syndrome induced by carbamazepine in southern Han Chinese: genetic markers besides B*1502? Basic Clin Pharmacol Toxicol. 2012;111(1):58–64.PubMed

Hsiao YH, Hui RC, Wu T, et al. Genotype–phenotype association between HLA and carbamazepine-induced hypersensitivity reactions: strength and clinical correlations. Journal of dermatological science. 2014;73(2):101–9.PubMedCrossRef

10.

Kaniwa N, Saito Y, Aihara M, et al. HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens–Johnson syndrome and toxic epidermal necrolysis. Pharmacogenomics. 2008;9(11):1617–22.PubMedCrossRef

11.

Kang HR, Jee YK, Kim YS, et al. Positive and negative associations of HLA class I alleles with allopurinol-induced SCARs in Koreans. Pharmacogenet Genomics. 2011;21(5):303–7.PubMedCrossRef

12.

Tassaneeyakul W, Jantararoungtong T, Chen P, et al. Strong association between HLA-B*5801 and allopurinol-induced Stevens–Johnson syndrome and toxic epidermal necrolysis in a Thai population. Pharmacogenet Genomics. 2009;19(9):704–9.PubMedCrossRef

13.

Hung SI, Chung WH, Liou LB, et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci USA. 2005;102(11):4134–9.PubMedCentralPubMedCrossRef

14.

Ikeda H, Takahashi Y, Yamazaki E, et al. HLA class I markers in Japanese patients with carbamazepine-induced cutaneous adverse reactions. Epilepsia. 2010;51(2):297–300.PubMedCrossRef

15.

Niihara H, Kakamu T, Fujita Y, et al. HLA-A31 strongly associates with carbamazepine-induced adverse drug reactions but not with carbamazepine-induced lymphocyte proliferation in a Japanese population. J Dermatol. 2012;39(7):594–601.PubMedCrossRef

16.

Ozeki T, Mushiroda T, Yowang A, et al. Genome-wide association study identifies HLA-A*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population. Hum Mol Genet. 2011;20(5):1034–41.PubMedCrossRef

17.

Cheung YK, Cheng SH, Chan EJ, et al. HLA-B alleles associated with severe cutaneous reactions to antiepileptic drugs in Han Chinese. Epilepsia. 2013;54(7):1307–14.PubMedCrossRef

18.

Hung SI, Chung WH, Liu ZS, et al. Common risk allele in aromatic antiepileptic-drug induced Stevens–Johnson syndrome and toxic epidermal necrolysis in Han Chinese. Pharmacogenomics. 2010;11(3):349–56.PubMedCrossRef

19.

Locharernkul C, Loplumlert J, Limotai C, et al. Carbamazepine and phenytoin induced Stevens–Johnson syndrome is associated with HLA-B*1502 allele in Thai population. Epilepsia. 2008;49(12):2087–91.PubMedCrossRef

20.

Kim SH, Kim M, Lee KW, et al. HLA-B*5901 is strongly associated with methazolamide-induced Stevens–Johnson syndrome/toxic epidermal necrolysis. Pharmacogenomics. 2010;11(6):879–84.PubMedCrossRef

21.

Lonjou C, Borot N, Sekula P, et al. A European study of HLA-B in Stevens–Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet Genomics. 2008;18(2):99–107.PubMedCrossRef

22.

Mehta TY, Prajapati LM, Mittal B, et al. Association of HLA-B*1502 allele and carbamazepine-induced Stevens–Johnson syndrome among Indians. Indian J Dermatol Venereol Leprol. 2009;75(6):579–82.PubMedCrossRef

23.

Tangamornsuksan W, Chaiyakunapruk N, Somkrua R, et al. Relationship between the HLA-B*1502 allele and carbamazepine-induced Stevens–Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis. JAMA Dermatol. 2013;149(9):1025–32.PubMedCrossRef

24.

Chung WH, Hung SI. Recent advances in the genetics and immunology of Stevens–Johnson syndrome and toxic epidermal necrosis. J Dermatol Sci. 2012;66(3):190–6.PubMedCrossRef

25.

Chen P, Lin JJ, Lu CS, et al. Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan. N Engl J Med. 2011;364(12):1126–33.PubMedCrossRef

26.

Hershfield MS, Callaghan JT, Tassaneeyakul W, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing. Clin Pharmacol Ther. 2013;93(2):153–8.PubMedCentralPubMedCrossRef

27.

Genin E, Chen DP, Hung SI, et al. HLA-A*31:01 and different types of carbamazepine-induced severe cutaneous adverse reactions: an international study and meta-analysis. Pharmacogenomics J. 2014;14(3):281–8.PubMedCrossRef

28.

Shear NH, Spielberg SP. Anticonvulsant hypersensitivity syndrome: in vitro assessment of risk. J Clin Investig. 1988;82(6):1826–32.PubMedCentralPubMedCrossRef

29.

Shear NH, Spielberg SP, Grant DM, et al. Differences in metabolism of sulfonamides predisposing to idiosyncratic toxicity. Ann Intern Med. 1986;105(2):179–84.PubMedCrossRef

30.

Chung WH, Chang WC, Lee YS, et al. Genetic variants associated with phenytoin-related severe cutaneous adverse reactions. JAMA. 2014;312(5):525–34.PubMedCrossRef

31.

Kesavan R, Narayan SK, Adithan C. Influence of CYP2C9 and CYP2C19 genetic polymorphisms on phenytoin-induced neurological toxicity in Indian epileptic patients. Eur J Clin Pharmacol. 2010;66(7):689–96.PubMedCrossRef

32.

Depondt C, Godard P, Espel RS, et al. A candidate gene study of antiepileptic drug tolerability and efficacy identifies an association of CYP2C9 variants with phenytoin toxicity. Eur J Neurol Off J Eur Fed Neurol Soc. 2011;18(9):1159–64.

33.

Ciccacci C, Di Fusco D, Marazzi MC, et al. Association between CYP2B6 polymorphisms and nevirapine-induced SJS/TEN: a pharmacogenetics study. Eur J Clin Pharmacol. 2013;69(11):1909–16.PubMedCrossRef

34.

Lerch M, Pichler WJ. The immunological and clinical spectrum of delayed drug-induced exanthems. Curr Opin Allergy Clin Immunol. 2004;4(5):411–9.PubMedCrossRef

35.

Pichler WJ. Pharmacological interaction of drugs with antigen-specific immune receptors: the p-i concept. Curr Opin Allergy Clin Immunol. 2002;2(4):301–5.PubMedCrossRef

36.

Yang CW, Hung SI, Juo CG, et al. HLA-B*1502-bound peptides: implications for the pathogenesis of carbamazepine-induced Stevens–Johnson syndrome. J Allergy Clin Immunol. 2007;120(4):870–7.PubMedCrossRef

37.

Wei CY, Chung WH, Huang HW, et al. Direct interaction between HLA-B and carbamazepine activates T cells in patients with Stevens–Johnson syndrome. J Allergy Clin Immunol. 2012;129(6):1562–9 (e5).PubMedCrossRef

38.

Torres MJ, Mayorga C, Garcia JJ, et al. New aspects in betalactam recognition. Clin Exp Allergy. 1998;28(Suppl 4):25–8.PubMed

39.

Ko TM, Chung WH, Wei CY, et al. Shared and restricted T-cell receptor use is crucial for carbamazepine-induced Stevens–Johnson syndrome. J Allergy Clin Immunol. 2011;128(6):1266–76 (e11).PubMedCrossRef

40.

Posadas SJ, Padial A, Torres MJ, et al. Delayed reactions to drugs show levels of perforin, granzyme B, and Fas-L to be related to disease severity. J Allergy Clin Immunol. 2002;109(1):155–61.PubMedCrossRef

41.

Nassif A, Moslehi H, Le Gouvello S, et al. Evaluation of the potential role of cytokines in toxic epidermal necrolysis. J Investig Dermatol. 2004;123(5):850–5.PubMedCrossRef

42.

Caproni M, Torchia D, Schincaglia E, et al. Expression of cytokines and chemokine receptors in the cutaneous lesions of erythema multiforme and Stevens–Johnson syndrome/toxic epidermal necrolysis. Br J Dermatol. 2006;155(4):722–8.PubMedCrossRef

43.

Liu ZG. Molecular mechanism of TNF signaling and beyond. Cell Res. 2005;15(1):24–7.PubMedCrossRef

44.

Chavez-Galan L, Arenas-Del Angel MC, Zenteno E, et al. Cell death mechanisms induced by cytotoxic lymphocytes. Cell Mol Immunol. 2009;6(1):15–25.PubMedCentralPubMedCrossRef

45.

Schroder K, Hertzog PJ, Ravasi T, et al. Interferon-gamma: an overview of signals, mechanisms and functions. J Leukoc Biol. 2004;75(2):163–89.PubMedCrossRef

46.

Steimle V, Siegrist CA, Mottet A, et al. Regulation of MHC class II expression by interferon-gamma mediated by the transactivator gene CIITA. Science. 1994;265(5168):106–9.PubMedCrossRef

47.

Fruh K, Yang Y. Antigen presentation by MHC class I and its regulation by interferon gamma. Curr Opin Immunol. 1999;11(1):76–81.PubMedCrossRef

48.

Paquet P, Paquet F, Al Saleh W, et al. Immunoregulatory effector cells in drug-induced toxic epidermal necrolysis. Am J Dermatopathol. 2000;22(5):413–7.PubMedCrossRef

49.

Correia O, Delgado L, Barbosa IL, et al. Increased interleukin 10, tumor necrosis factor alpha, and interleukin 6 levels in blister fluid of toxic epidermal necrolysis. J Am Acad Dermatol. 2002;47(1):58–62.PubMedCrossRef

50.

Tapia B, Padial A, Sanchez-Sabate E, et al. Involvement of CCL27–CCR10 interactions in drug-induced cutaneous reactions. J Allergy Clin Immunol. 2004;114(2):335–40.PubMedCrossRef

51.

Chung WH, Hung SI. Genetic markers and danger signals in Stevens–Johnson syndrome and toxic epidermal necrolysis. Allergol Int. 2010;59(4):325–32.PubMedCrossRef

52.

Chung WH, Hung SI, Yang JY, et al. Granulysin is a key mediator for disseminated keratinocyte death in Stevens–Johnson syndrome and toxic epidermal necrolysis. Nat Med. 2008;14(12):1343–50.PubMedCrossRef

53.

Viard I, Wehrli P, Bullani R, et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science. 1998;282(5388):490–3.PubMedCrossRef

54.

Nassif A, Bensussan A, Dorothee G, et al. Drug specific cytotoxic T-cells in the skin lesions of a patient with toxic epidermal necrolysis. J Investig Dermatol. 2002;118(4):728–33.PubMedCrossRef

55.

Wang CW, Chung WH, Cheng YF, et al. A new nucleic acid–based agent inhibits cytotoxic T lymphocyte-mediated immune disorders. J Allergy Clin Immunol. 2013;132(3):713–22 (e11).PubMedCrossRef

56.

Finn MW, Clayberger C, Krensky AM. Expression and purification of 15 kDa granulysin utilizing an insect cell secretion system. Protein Expr Purif. 2011;75(1):70–4.PubMedCentralPubMedCrossRef

57.

Tewary P, Yang D, de la Rosa G, et al. Granulysin activates antigen-presenting cells through TLR4 and acts as an immune alarmin. Blood. 2010;116(18):3465–74.PubMedCentralPubMedCrossRef

58.

Schlapbach C, Zawodniak A, Irla N, et al. NKp46+ cells express granulysin in multiple cutaneous adverse drug reactions. Allergy. 2011;66(11):1469–76.PubMedCrossRef

59.

Fournier S, Bastuji-Garin S, Mentec H, et al. Toxic epidermal necrolysis associated with Mycoplasma pneumoniae infection. Eur J Clin Microbiol Infect Dis. 1995;14(6):558–9.PubMedCrossRef

60.

Mulvey JM, Padowitz A, Lindley-Jones M, et al. Mycoplasma pneumoniae associated with Stevens Johnson syndrome. Anaesth Intensive Care. 2007;35(3):414–7.PubMed

61.

Harr T, French LE. Toxic epidermal necrolysis and Stevens–Johnson syndrome. Orphanet J Rare Dis. 2010;5:39.PubMedCentralPubMedCrossRef

62.

Chung WH, Shih SR, Chang CF, et al. Clinicopathologic analysis of coxsackievirus a6 new variant induced widespread mucocutaneous bullous reactions mimicking severe cutaneous adverse reactions. J Infect Dis. 2013;208(12):1968–78.PubMedCrossRef

63.

Rzany B, Mockenhaupt M, Baur S, et al. Epidemiology of erythema exsudativum multiforme majus, Stevens–Johnson syndrome, and toxic epidermal necrolysis in Germany (1990–1992): structure and results of a population-based registry. Journal of clinical epidemiology. 1996;49(7):769–73.PubMedCrossRef

64.

Mockenhaupt M. The current understanding of Stevens–Johnson syndrome and toxic epidermal necrolysis. Expert review of clinical immunology. 2011;7(6):803–13 (quiz 14–5).PubMedCrossRef

65.

Mockenhaupt M, Viboud C, Dunant A, et al. Stevens–Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Investig Dermatol. 2008;128(1):35–44.PubMedCrossRef

66.

Huang LY, Liao WC, Chiou CC, et al. Fatal toxic epidermal necrolysis induced by carbamazepine treatment in a patient who previously had carbamazepine-induced Stevens–Johnson syndrome. J Formos Med Assoc Taiwan yi Zhi. 2007;106(12):1032–7.PubMedCrossRef

67.

Auquier-Dunant A, Mockenhaupt M, Naldi L, et al. Correlations between clinical patterns and causes of erythema multiforme majus, Stevens–Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study. Arch Dermatol. 2002;138(8):1019–24.PubMedCrossRef

68.

Assier H, Bastuji-Garin S, Revuz J, et al. Erythema multiforme with mucous membrane involvement and Stevens–Johnson syndrome are clinically different disorders with distinct causes. Arch Dermatol. 1995;131(5):539–43.PubMedCrossRef

69.

Bastuji-Garin S, Rzany B, Stern RS, et al. Clinical classification of cases of toxic epidermal necrolysis, Stevens–Johnson syndrome, and erythema multiforme. Arch Dermatol. 1993;129(1):92–6.PubMedCrossRef

70.

Revuz J, Penso D, Roujeau JC, et al. Toxic epidermal necrolysis: clinical findings and prognosis factors in 87 patients. Arch Dermatol. 1987;123(9):1160–5.PubMedCrossRef

71.

Rajaratnam R, Mann C, Balasubramaniam P, et al. Toxic epidermal necrolysis: retrospective analysis of 21 consecutive cases managed at a tertiary centre. Clin Exp Dermatol. 2010;35(8):853–62.PubMedCrossRef

72.

Meneux E, Wolkenstein P, Haddad B, et al. Vulvovaginal involvement in toxic epidermal necrolysis: a retrospective study of 40 cases. Obstet Gynecol. 1998;91(2):283–7.PubMedCrossRef

73.

Gueudry J, Roujeau JC, Binaghi M, et al. Risk factors for the development of ocular complications of Stevens–Johnson syndrome and toxic epidermal necrolysis. Arch Dermatol. 2009;145(2):157–62.PubMedCrossRef

74.

Sotozono C, Ueta M, Koizumi N, et al. Diagnosis and treatment of Stevens–Johnson syndrome and toxic epidermal necrolysis with ocular complications. Ophthalmology. 2009;116(4):685–90.PubMedCrossRef

75.

Pereira FA, Mudgil AV, Rosmarin DM. Toxic epidermal necrolysis. J Am Acad Dermatol. 2007;56(2):181–200.PubMedCrossRef

76.

Lebargy F, Wolkenstein P, Gisselbrecht M, et al. Pulmonary complications in toxic epidermal necrolysis: a prospective clinical study. Intensive care Med. 1997;23(12):1237–44.PubMedCrossRef

77.

de Prost N, Mekontso-Dessap A, Valeyrie-Allanore L, et al. Acute respiratory failure in patients with toxic epidermal necrolysis: clinical features and factors associated with mechanical ventilation. Crit Care Med. 2014;42(1):118–28.PubMedCrossRef

78.

Michel P, Joly P, Ducrotte P, et al. Ileal involvement in toxic epidermal necrolysis (Lyell syndrome). Dig Dis Sci. 1993;38(10):1938–41.PubMedCrossRef

79.

Powell N, Munro JM, Rowbotham D. Colonic involvement in Stevens–Johnson syndrome. Postgrad Med J. 2006;82(968):e10.PubMedCentralPubMedCrossRef

80.

Hung CC, Liu WC, Kuo MC, et al. Acute renal failure and its risk factors in Stevens–Johnson syndrome and toxic epidermal necrolysis. Am J Nephrol. 2009;29(6):633–8.PubMedCrossRef

81.

Weinand C, Xu W, Perbix W, et al. 27 years of a single burn centre experience with Stevens–Johnson syndrome and toxic epidermal necrolysis: analysis of mortality risk for causative agents. Burns. 2013;39(7):1449–55.PubMedCrossRef

82.

de Prost N, Ingen-Housz-Oro S, Duong T, et al. Bacteremia in Stevens–Johnson syndrome and toxic epidermal necrolysis: epidemiology, risk factors, and predictive value of skin cultures. Medicine (Baltimore). 2010;89(1):28–36.PubMedCrossRef

83.

Sekula P, Dunant A, Mockenhaupt M, et al. Comprehensive survival analysis of a cohort of patients with Stevens–Johnson syndrome and toxic epidermal necrolysis. J Investig Dermatol. 2013;133(5):1197–204.PubMedCrossRef

84.

Garcia-Doval I, LeCleach L, Bocquet H, et al. Toxic epidermal necrolysis and Stevens–Johnson syndrome: does early withdrawal of causative drugs decrease the risk of death? Arch Dermatol. 2000;136(3):323–7.PubMedCrossRef

85.

Bastuji-Garin S, Fouchard N, Bertocchi M, et al. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Investig Dermatol. 2000;115(2):149–53.PubMedCrossRef

86.

Zhu QY, Ma L, Luo XQ, et al. Toxic epidermal necrolysis: performance of SCORTEN and the score-based comparison of the efficacy of corticosteroid therapy and intravenous immunoglobulin combined therapy in China. J Burn Care Res. 2012;33(6):e295–308.PubMedCrossRef

87.

Cartotto R, Mayich M, Nickerson D, et al. SCORTEN accurately predicts mortality among toxic epidermal necrolysis patients treated in a burn center. J Burn Care Res. 2008;29(1):141–6.PubMed

88.

Sekula P, Liss Y, Davidovici B, et al. Evaluation of SCORTEN on a cohort of patients with Stevens–Johnson syndrome and toxic epidermal necrolysis included in the RegiSCAR study. J Burn Care Res. 2011;32(2):237–45.PubMedCrossRef

89.

Guegan S, Bastuji-Garin S, Poszepczynska-Guigne E, et al. Performance of the SCORTEN during the first five days of hospitalization to predict the prognosis of epidermal necrolysis. J Investig Dermatol. 2006;126(2):272–6.PubMedCrossRef

90.

Fellahi A, Zouhair K, Amraoui A, et al. Stevens–Johnson and Lyell syndromes: mucocutaneous and ocular sequels in 43 cases [in French]. Ann Dermatol Venereol. 2011;138(2):88–92.PubMedCrossRef

91.

Morales ME, Purdue GF, Verity SM, et al. Ophthalmic manifestations of Stevens–Johnson syndrome and toxic epidermal necrolysis and relation to SCORTEN. Am J Ophthalmol. 2010;150(4):505–10 (e1).PubMedCrossRef

92.

Gaultier F, Rochefort J, Landru MM, et al. Severe and unrecognized dental abnormalities after drug-induced epidermal necrolysis. Arch Dermatol. 2009;145(11):1332–3.PubMedCrossRef

93.

Duong TA, de Prost N, Ingen-Housz-Oro S, et al. Stevens–Johnson syndrome and toxic epidermal necrolysis: follow-up of pulmonary function after remission. Br J Dermatol. 2015;172(2):400–5.PubMedCrossRef

94.

Dodiuk-Gad RP, Olteanu C, Hashimoto R, et al. Long-term emotional and physical complications of Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). 23rd World Congress of Dermatology; Vancouver; 2015.

95.

Quinn AM, Brown K, Bonish BK, et al. Uncovering histologic criteria with prognostic significance in toxic epidermal necrolysis. Arch Dermatol. 2005;141(6):683–7.PubMedCrossRef

96.

Fujita Y, Yoshioka N, Abe R, et al. Rapid immunochromatographic test for serum granulysin is useful for the prediction of Stevens–Johnson syndrome and toxic epidermal necrolysis. J Am Acad Dermatol. 2011;65(1):65–8.PubMedCrossRef

97.

Nigen S, Knowles SR, Shear NH. Drug eruptions: approaching the diagnosis of drug-induced skin diseases. J Drugs Dermatol. 2003;2(3):278–99.PubMed

98.

Eisen ER, Fish J, Shear NH. Management of drug-induced toxic epidermal necrolysis. J Cutan Med Surg. 2000;4(2):96–102.PubMed

99.

Mockenhaupt M. Stevens–Johnson syndrome and toxic epidermal necrolysis: clinical patterns, diagnostic considerations, etiology, and therapeutic management. Semin Cutan Med Surg. 2014;33(1):10–6.PubMedCrossRef

100.

Chavan R, el-Azhary R. Cutaneous graft-versus-host disease: rationales and treatment options. Dermatol Ther. 2011;24(2):219–28.PubMedCrossRef

101.

Mandelcorn R, Shear NH. Lupus-associated toxic epidermal necrolysis: a novel manifestation of lupus? J Am Acad Dermatol. 2003;48(4):525–9.PubMedCrossRef

102.

Paradela S, Martinez-Gomez W, Fernandez-Jorge B, et al. Toxic epidermal necrolysis-like acute cutaneous lupus erythematosus. Lupus. 2007;16(9):741–5.PubMedCrossRef

103.

Baldwin BT, Lien MH, Khan H, et al. Case of fatal toxic epidermal necrolysis due to cardiac catheterization dye. J Drugs Dermatol. 2010;9(7):837–40.PubMed

104.

Ball R, Ball LK, Wise RP, et al. Stevens–Johnson syndrome and toxic epidermal necrolysis after vaccination: reports to the vaccine adverse event reporting system. Pediatr Infect Dis J. 2001;20(2):219–23.PubMedCrossRef

105.

Sassolas B, Haddad C, Mockenhaupt M, et al. ALDEN, an algorithm for assessment of drug causality in Stevens–Johnson syndrome and toxic epidermal necrolysis: comparison with case–control analysis. Clin Pharmacol Ther. 2010;88(1):60–8.PubMedCrossRef

106.

Heelan K, Shear NH. Cutaneous drug reactions in children: an update. Paediatr Drugs. 2013;15(6):493–503.PubMedCrossRef

107.

Pavlos R, Mallal S, Ostrov D, et al. Fever, rash, and systemic symptoms: understanding the role of virus and HLA in severe cutaneous drug allergy. J Allergy Clin Immunol Pract. 2014;2(1):21–33.PubMedCentralPubMedCrossRef

108.

Pichler WJ, Tilch J. The lymphocyte transformation test in the diagnosis of drug hypersensitivity. Allergy. 2004;59(8):809–20.PubMedCrossRef

109.

Porebski G, Pecaric-Petkovic T, Groux-Keller M, et al. In vitro drug causality assessment in Stevens–Johnson syndrome—alternatives for lymphocyte transformation test. Clin Exp Allergy. 2013;43(9):1027–37.PubMedCrossRef

110.

Schwartz RA, McDonough PH, Lee BW. Toxic epidermal necrolysis: part I. Introduction, history, classification, clinical features, systemic manifestations, etiology, and immunopathogenesis. J Am Acad Dermatol. 2013;69(2):173 e1–13 (quiz 85–6).

111.

Valeyrie-Allanore L, Bastuji-Garin S, Guegan S, et al. Prognostic value of histologic features of toxic epidermal necrolysis. J Am Acad Dermatol. 2013;68(2):e29–35.PubMedCrossRef

112.

Endorf FW, Cancio LC, Gibran NS. Toxic epidermal necrolysis clinical guidelines. J Burn Care Res. 2008;29(5):706–12.PubMedCrossRef

113.

Fromowitz JS, Ramos-Caro FA, Flowers FP, et al. Practical guidelines for the management of toxic epidermal necrolysis and Stevens–Johnson syndrome. Int J Dermatol. 2007;46(10):1092–4.PubMedCrossRef

114.

Valeyrie-Allanore L, Ingen-Housz-Oro S, Chosidow O, et al. French referral center management of Stevens–Johnson syndrome/toxic epidermal necrolysis. Dermatol Sin. 2013;31(4):191–5.CrossRef

115.

Shiga S, Cartotto R. What are the fluid requirements in toxic epidermal necrolysis? J Burn Care Res. 2010;31(1):100–4.PubMedCrossRef

116.

Fernando SL. The management of toxic epidermal necrolysis. Australas J Dermatol. 2012;53(3):165–71.PubMedCrossRef

117.

Mayes T, Gottschlich M, Khoury J, et al. Energy requirements of pediatric patients with Stevens–Johnson syndrome and toxic epidermal necrolysis. Nutr Clin Pract. 2008;23(5):547–50.PubMedCrossRef

118.

Bachot N, Revuz J, Roujeau JC. Intravenous immunoglobulin treatment for Stevens–Johnson syndrome and toxic epidermal necrolysis: a prospective noncomparative study showing no benefit on mortality or progression. Arch Dermatol. 2003;139(1):33–6.PubMedCrossRef

119.

Faye O, Roujeau JC. Treatment of epidermal necrolysis with high-dose intravenous immunoglobulins (IV Ig): clinical experience to date. Drugs. 2005;65(15):2085–90.PubMedCrossRef

120.

Lee HY, Lim YL, Thirumoorthy T, et al. The role of intravenous immunoglobulin in toxic epidermal necrolysis: a retrospective analysis of 64 patients managed in a specialized centre. Br J Dermatol. 2013;169(6):1304–9.PubMedCrossRef

121.

Valeyrie-Allanore L, Wolkenstein P, Brochard L, et al. Open trial of ciclosporin treatment for Stevens–Johnson syndrome and toxic epidermal necrolysis. Br J Dermatol. 2010;163(4):847–53.PubMedCrossRef

122.

Arevalo JM, Lorente JA, Gonzalez-Herrada C, et al. Treatment of toxic epidermal necrolysis with cyclosporin A. J Trauma. 2000;48(3):473–8.PubMedCrossRef

123.

Kirchhof MG, Miliszewski MA, Sikora S, et al. Retrospective review of Stevens-Johnson syndrome/toxic epidermal necrolysis treatment comparing intravenous immunoglobulin with cyclosporine. J Am Acad Dermatol. 2014;71(5):941–7.PubMedCrossRef

124.

Schneck J, Fagot JP, Sekula P, et al. Effects of treatments on the mortality of Stevens–Johnson syndrome and toxic epidermal necrolysis: a retrospective study on patients included in the prospective EuroSCAR study. J Am Acad Dermatol. 2008;58(1):33–40.PubMedCrossRef

125.

Dodiuk-Gad RP, Chung WH, Yang CH, et al. The 8th International Congress on Cutaneous Adverse Drug Reactions, Taiwan, 2013: focus on severe cutaneous adverse reactions. Drug Saf. 2014;37(6):459–64.PubMedCrossRef

126.

Kardaun SH, Jonkman MF. Dexamethasone pulse therapy for Stevens–Johnson syndrome/toxic epidermal necrolysis. Acta dermato-venereol. 2007;87(2):144–8.CrossRef

127.

Scott-Lang V, Tidman M, McKay D. Toxic epidermal necrolysis in a child successfully treated with infliximab. Pediatr Dermatol. 2014;31(4):532–4.PubMedCrossRef

128.

Gubinelli E, Canzona F, Tonanzi T, et al. Toxic epidermal necrolysis successfully treated with etanercept. J Dermatol. 2009;36(3):150–3.PubMedCrossRef

129.

Paradisi A, Abeni D, Bergamo F, et al. Etanercept therapy for toxic epidermal necrolysis. J Am Acad Dermatol. 2014;71(2):278–83.PubMedCrossRef

130.

Del Pozzo-Magana BR, Lazo-Langner A, Carleton B, et al. A systematic review of treatment of drug-induced Stevens–Johnson syndrome and toxic epidermal necrolysis in children. J Popul Ther Clin Pharmacol. 2011;18:e121–33.PubMed

131.

Koh MJ, Tay YK. Stevens–Johnson syndrome and toxic epidermal necrolysis in Asian children. J Am Acad Dermatol. 2010;62(1):54–60.PubMedCrossRef

132.

Hamilton GM, Fish J. Pediatric toxic epidermal necrolysis: an institutional review of patients admitted to an intensive care unit. J Burn Care Res. 2013;34(6):e351–8.PubMedCrossRef

133.

Paquet P, Pierard GE. Topical treatment options for drug-induced toxic epidermal necrolysis (TEN). Expert Opin Pharmacother. 2010;11(15):2447–58.PubMedCrossRef

134.

Abela C, Hartmann CE, De Leo A, et al. Toxic epidermal necrolysis (TEN): the Chelsea and Westminster Hospital wound management algorithm. J Plast Reconstr Aesthet Surg. 2014;67(8):1026–32.PubMedCrossRef

135.

Fu Y, Gregory DG, Sippel KC, et al. The ophthalmologist’s role in the management of acute Stevens–Johnson syndrome and toxic epidermal necrolysis. Ocul Surf. 2010;8(4):193–203.PubMedCrossRef

136.

Shay E, Kheirkhah A, Liang L, et al. Amniotic membrane transplantation as a new therapy for the acute ocular manifestations of Stevens–Johnson syndrome and toxic epidermal necrolysis. Surv Ophthalmol. 2009;54(6):686–96.PubMedCentralPubMedCrossRef

137.

Hsu M, Jayaram A, Verner R, et al. Indications and outcomes of amniotic membrane transplantation in the management of acute Stevens–Johnson syndrome and toxic epidermal necrolysis: a case–control study. Cornea. 2012;31(12):1394–402.PubMedCrossRef

138.

Tomlins PJ, Parulekar MV, Rauz S. “Triple-TEN” in the treatment of acute ocular complications from toxic epidermal necrolysis. Cornea. 2013;32(3):365–9.PubMedCrossRef

139.

Meneux E, Paniel BJ, Pouget F, et al. Vulvovaginal sequelae in toxic epidermal necrolysis. J Reprod Med. 1997;42(3):153–6.PubMed

140.

Niemeijer IC, van Praag MC, van Gemund N. Relevance and consequences of erythema multiforme, Stevens–Johnson syndrome and toxic epidermal necrolysis in gynecology. Arch Gynecol Obstet. 2009;280(5):851–4.PubMedCrossRef

141.

Kaser DJ, Reichman DE, Laufer MR. Prevention of vulvovaginal sequelae in Stevens–Johnson syndrome and toxic epidermal necrolysis. Rev Obstet Gynecol. 2011;4(2):81–5.PubMedCentralPubMed

142.

Struck MF, Illert T, Liss Y, et al. Toxic epidermal necrolysis in pregnancy: case report and review of the literature. J Burn Care Res. 2010;31(5):816–21.PubMedCrossRef

143.

Rodriguez G, Trent JT, Mirzabeigi M, et al. Toxic epidermal necrolysis in a mother and fetus. J Am Acad Dermatol. 2006;55(5 Suppl):S96–8.PubMedCrossRef

144.

Claessens N, Delbeke L, Lambert J, et al. Toxic epidermal necrolysis associated with treatment for preterm labor. Dermatology. 1998;196(4):461–2.PubMedCrossRef

145.

Vasicka AI, Lin TJ, Das BK. Erythema multiforme exudativum (Stevens–Johnson syndrome) at term pregnancy: report of one case. Obstet Gynecol. 1958;12(2):225–9.PubMed

146.

Dube N, Adewusi E, Summers R. Risk of nevirapine-associated Stevens–Johnson syndrome among HIV-infected pregnant women: the Medunsa National Pharmacovigilance Centre, 2007–2012. S Afr Med J. 2013;103(5):322–5.PubMedCrossRef

147.

Knight L, Muloiwa R, Dlamini S, et al. Factors associated with increased mortality in a predominantly HIV-infected population with Stevens Johnson syndrome and toxic epidermal necrolysis. PloS One. 2014;9(4):e93543.PubMedCentralPubMedCrossRef

148.

Mittmann N, Knowles SR, Gomez M, et al. Evaluation of the extent of under-reporting of serious adverse drug reactions: the case of toxic epidermal necrolysis. Drug Saf. 2004;27(7):477–87.PubMedCrossRef

149.

Sanchez-Lopez MP, Dresch V. The 12-Item General Health Questionnaire (GHQ-12): reliability, external validity and factor structure in the Spanish population. Psicothema. 2008;20(4):839–43.

150.

Man CB, Kwan P, Baum L, et al. Association between HLA-B*1502 allele and antiepileptic drug–induced cutaneous reactions in Han Chinese. Epilepsia. 2007;48(5):1015–8.PubMedCrossRef

151.

Carr DF, Chaponda M, Jorgensen AL, et al. Association of human leukocyte antigen alleles and nevirapine hypersensitivity in a Malawian HIV-infected population. Clin Infect Dis. 2013;56(9):1330–9.PubMedCentralPubMedCrossRef

152.

Levi N, Bastuji-Garin S, Mockenhaupt M, et al. Medications as risk factors of Stevens–Johnson syndrome and toxic epidermal necrolysis in children: a pooled analysis. Pediatrics. 2009;123(2):e297–304.PubMedCrossRef

153.

Saka B, Barro-Traore F, Atadokpede FA, et al. Stevens–Johnson syndrome and toxic epidermal necrolysis in sub-Saharan Africa: a multicentric study in four countries. Int J Dermatol. 2013;52(5):575–9.PubMedCrossRef

Titel: Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: An Update
verfasst von: Roni P. Dodiuk-Gad
Wen-Hung Chung
Laurence Valeyrie-Allanore
Neil H. Shear
Publikationsdatum: 01.12.2015
Verlag: Springer International Publishing
Erschienen in: American Journal of Clinical Dermatology / Ausgabe 6/2015
Print ISSN: 1175-0561
Elektronische ISSN: 1179-1888
DOI: https://doi.org/10.1007/s40257-015-0158-0

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Dermatologie

Hirsutismus bei PCOS: Laser- und Lichttherapien helfen

26.04.2024 Hirsutismus Nachrichten

Laser- und Lichtbehandlungen können bei Frauen mit polyzystischem Ovarialsyndrom (PCOS) den übermäßigen Haarwuchs verringern und das Wohlbefinden verbessern – bei alleiniger Anwendung oder in Kombination mit Medikamenten.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

22.04.2024 DGIM 2024 Nachrichten

Um Menschen nach der Flucht aus einem Krisengebiet bestmöglich medizinisch betreuen zu können, ist es gut zu wissen, welche Erkrankungen im jeweiligen Herkunftsland häufig sind. Dabei hilft eine Internetseite der CDC (Centers for Disease Control and Prevention).

Kein Abstrich bei chronischen Wunden ohne Entzündungszeichen!

16.04.2024 DGIM 2024 Nachrichten

Den Reflex, eine oberflächliche chronische Hautwunde ohne Entzündungszeichen in jedem Fall abzustreichen, sollte man nach einer neuen „Klug-entscheiden“-Empfehlung unterdrücken.

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2015

Acknowledgement to Referees

New and Emerging Treatments for Rosacea

Quality of Life and Gastrointestinal Symptoms in Long-Term Treated Dermatitis Herpetiformis Patients: A Cross-Sectional Study in Finland

Effects of Helicobacter pylori Eradication in Chronic Spontaneous Urticaria: Results from a Retrospective Cohort Study

Prurigo Pigmentosa: Literature Review